Lumida
/IBRX
⌘K
Immunitybio Inc

Immunitybio Inc

IBRX
$7.91USD+2.46%+0.19 today

MARKET CAP

8.4B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$2
$12

AI Summary

Stalk
StalkMedium

IBRX remains in a Stage 2 consolidation above its rising 200DMA after the mid-Feb parabolic spike and collapse. Short-term EMAs (9/20/50) are flat and price sits slightly below the cluster, with neutral RSI and Options Score signaling no clear timing edge. Medium-term bias stays bullish in this range-bound structure, but execution should await support near the lower range or a decisive reclaim of the EMA cluster.

  • Q2 2026 net revenues $50.7 M, up 92% YoY.
  • ANKTIVA revenues projected to hit $210 M (+85% YoY) in 2026.
  • Negative profitability factors suggest unsustainable margin structure.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$934,000$240,000$622,000$14.7M$113.3M
YoY %-74.3%+159.2%+2270.6%+668.3%
P / Sales2533.8x7948.0x4285.0x121.6x16.1x
EV / Sales3103.1x10805.9x5420.3x171.0x24.1x
Gross Profit, Adj.$934,000$240,000$622,000$14.7M$112.5M
YoY %-74.3%+159.2%+2270.6%+663.2%
Margin %100.0%100.0%100.0%100.0%99.3%
EV / Gross Profit3103.1x10805.9x5420.3x171.0x24.3x
EBITDA, Adj.$-311.2M$-332.4M$-342.9M$-326.6M$-240.5M
YoY %-6.8%-3.2%+4.7%+26.4%
Margin %-33314.6%-138482.1%-55120.9%-2215.2%-212.3%
EV / EBITDA-9.3x-7.8x-9.8x-7.7x-11.4x
EBIT$-330.3M$-351.3M$-362.3M$-344.2M$-256.0M
YoY %-6.4%-3.1%+5.0%+25.6%
Margin %-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
EV / EBIT-8.8x-7.4x-9.3x-7.3x-10.7x
Net Income$-346.8M$-416.6M$-583.2M$-413.6M$-351.4M
YoY %-20.1%-40.0%+29.1%+15.0%
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (GAAP)-$0.89-$1.04-$1.15-$0.62-$0.38
YoY %-16.9%-10.6%+46.1%+38.7%